MAY 1 5 2002 W

Docket No. 20558-4017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): De Ferra et al.

Group Art Unit: 16

1626

Serial No.:

09/982,468

Examiner:

Murray, Joseph A

Filed:

October 18, 2001

For:

Purifying Process for Phosphatidylserine

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

1.

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

For each of the following items listed on the enclosed copy of Form PTO-1449 that is

	not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:				
	DE 199117249 (English abstract enclosed)				
2.	For each of the following items listed on the enclosed copy of Form PTO-1449 the not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.	Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed				
1.	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:				
	37 C.F.R. §1.97(b)(1), within three months of the filing date of a national				

application other than a CPA; or

			national stage as set forth in §1.491 in an international application; or		
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or		
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.		
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.			
6.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):			
			A check in the amount of \$180.00 is enclosed in payment of the fee.		
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.		
7.		it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue d is accompanied by:		
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and		
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 clow.		
8.			is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with:		
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);		
		b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).		

		c. 🗌	The fees due under 3 paragraph 11 below.	7 C.F.R. §§1.17(h) and 1.17(p) are paid as set forth in		
9.		I hereby certify that each item of information contained in this Information I Statement was first cited in a communication from a foreign patent office in counterpart foreign application not more than three months prior to the filing Information Disclosure Statement.				
		filed h counte was kr	erewith was cited in a rpart foreign applicati nown to any individua	of information in the Information Disclosure Statement communication from a foreign patent office in a on or, to my knowledge after making reasonable inquiry, I designated in §1.56(c) more than three months prior to Disclosure Statement.		
10.		This document is accompanied by \(\subseteq a \) Search Report \(\subseteq \) Communication which was cited in a corresponding \(\supseteq \) PCT or \(\subseteq \) Foreign counterpart application				
11.		A check in the amount of \$180.00 is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).				
		Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
	X	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. <u>13-4500</u> , Order No. <u>0558-4017</u> . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
				Respectfully submitted, MORGAN & FINNEGAN, L.L.P.		
Dat	ed: <u>M</u>	ay 15, 2	2002	By: James P. Demers Registration No. 34,320		
Cor	respo	ndence .	Address:	·		
			NNEGAN, L.L.P.			
		Avenue	0154-0053			
		•	Telephone			
			Facsimile			